Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Resverlogix Corp (RVX) Common NPV

Sell:2.80 CAD Buy:2.82 CAD Change: 0.11 CAD (4.06%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:2.80 CAD
Buy:2.82 CAD
Change: 0.11 CAD (4.06%)
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:2.80 CAD
Buy:2.82 CAD
Change: 0.11 CAD (4.06%)
Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Resverlogix Corp is Canada-based clinical-stage biotechnology company. The Company is developing apabetalone (RVX-208), a molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects for patients with high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, dialysis, Alzheimer's disease, Fabry disease, other orphan diseases, and peripheral artery disease. Apabetalone is being studied in a Phase III trial, BETonMACE, in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL).

Contact details

Address:
300-4820 Richard Rd SW
CALGARY
T3E 6L1
Canada
Telephone:
+1 (403) 2549252
Website:
https://www.resverlogix.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
RVX
ISIN:
CA76128M1086
Market cap:
557.00 million CAD
Shares in issue:
204.39 million
Sector:
Biotechnology
Exchange:
Toronto Stock Exchange
Country:
Canada
Currency:
Canadian dollars
Indices:
n/a

Key personnel

  • Donald McCaffrey
    Chairman of the Board, President, Chief Executive Officer, Secretary
  • A. Brad Cann
    Chief Financial Officer
  • Jan Johansson
    Senior Vice President - Medical Affairs
  • Kenneth Lebioda
    Senior Vice President - Business & Corporate Development
  • Michael Sweeney
    Senior Vice President - Clinical Development
  • Norman Wong
    Chief Scientific Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.